Dr Reddys Laboratories (RDY) Total Non-Current Liabilities (2017 - 2026)
Dr Reddys Laboratories has reported Total Non-Current Liabilities over the past 10 years, most recently at $342.6 million for Q1 2026.
- For Q1 2026, Total Non-Current Liabilities rose 16.67% year-over-year to $342.6 million; the TTM value through Mar 2026 reached $342.6 million, up 16.67%, while the annual FY2026 figure was $342.6 million, 14.98% up from the prior year.
- Total Non-Current Liabilities for Q1 2026 was $342.6 million at Dr Reddys Laboratories, up from $293.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $342.6 million in Q1 2026 and troughed at $61.0 million in Q1 2023.
- A 5-year average of $187.8 million and a median of $131.6 million in 2024 define the central range for Total Non-Current Liabilities.
- Biggest five-year swings in Total Non-Current Liabilities: tumbled 44.6% in 2023 and later surged 123.16% in 2025.
- Year by year, Total Non-Current Liabilities stood at $110.2 million in 2022, then crashed by 44.6% to $61.0 million in 2023, then soared by 115.59% to $131.6 million in 2024, then soared by 123.16% to $293.7 million in 2025, then grew by 16.67% to $342.6 million in 2026.
- Business Quant data shows Total Non-Current Liabilities for RDY at $342.6 million in Q1 2026, $293.7 million in Q1 2025, and $131.6 million in Q1 2024.